Design of Adaptive Phase 1 Clinical Trials for Dose Escalation using the DEDUCE Application

[@aeky168]

What is advantage of 3+3 design?

[@thepartnership800]

Response from Dr. London: "easy to understand and conduct;
well known in the oncology scientific community;
requires very little time from a statistician, and therefore could be a lower cost"